JP2024503898A - ラパマイシン類似体及びその使用 - Google Patents

ラパマイシン類似体及びその使用 Download PDF

Info

Publication number
JP2024503898A
JP2024503898A JP2023544070A JP2023544070A JP2024503898A JP 2024503898 A JP2024503898 A JP 2024503898A JP 2023544070 A JP2023544070 A JP 2023544070A JP 2023544070 A JP2023544070 A JP 2023544070A JP 2024503898 A JP2024503898 A JP 2024503898A
Authority
JP
Japan
Prior art keywords
compounds
sulfur
nitrogen
oxygen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503898A5 (https=
JPWO2022159976A5 (https=
Inventor
ジョン オニール，デビッド
サイア，エディン
ウー アンソニー カン，セオン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2024503898A publication Critical patent/JP2024503898A/ja
Publication of JP2024503898A5 publication Critical patent/JP2024503898A5/ja
Publication of JPWO2022159976A5 publication Critical patent/JPWO2022159976A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023544070A 2021-01-22 2022-01-24 ラパマイシン類似体及びその使用 Pending JP2024503898A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163140523P 2021-01-22 2021-01-22
US63/140,523 2021-01-22
US202163202524P 2021-06-15 2021-06-15
US63/202,524 2021-06-15
PCT/US2022/070308 WO2022159976A1 (en) 2021-01-22 2022-01-24 Rapamycin analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2024503898A true JP2024503898A (ja) 2024-01-29
JP2024503898A5 JP2024503898A5 (https=) 2025-02-03
JPWO2022159976A5 JPWO2022159976A5 (https=) 2025-02-03

Family

ID=82549982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544070A Pending JP2024503898A (ja) 2021-01-22 2022-01-24 ラパマイシン類似体及びその使用

Country Status (9)

Country Link
US (1) US20220267352A1 (https=)
EP (1) EP4281463A4 (https=)
JP (1) JP2024503898A (https=)
KR (1) KR20230136625A (https=)
AU (1) AU2022209863A1 (https=)
BR (1) BR112023014287A2 (https=)
CA (1) CA3209086A1 (https=)
MX (1) MX2023008634A (https=)
WO (1) WO2022159976A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3914245A4 (en) 2019-01-22 2022-08-24 Aeovian Pharmaceuticals, Inc. MTORC-1 MODULATORS AND USES THEREOF
WO2021195599A1 (en) 2020-03-27 2021-09-30 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509248A (ja) * 1992-07-17 1995-10-12 スミスクライン・ビーチャム・コーポレイション ラパマイシン誘導体
JP2010500286A (ja) * 2006-07-25 2010-01-07 アボット・ラボラトリーズ 結晶形態のラパマイシン類似体
JP2013536182A (ja) * 2010-08-04 2013-09-19 メリル ライフ サイエンシズ ピーブィティ．エルティディ 抗増殖特性を有する新規４２−ｏ−（ヘテロアルコキシアルキル）ラパマイシン化合物の調製プロセス
WO2019241789A1 (en) * 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020154447A1 (en) * 2019-01-22 2020-07-30 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
WO2021113665A1 (en) * 2019-12-05 2021-06-10 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130232A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
US10683308B2 (en) * 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509248A (ja) * 1992-07-17 1995-10-12 スミスクライン・ビーチャム・コーポレイション ラパマイシン誘導体
JP2010500286A (ja) * 2006-07-25 2010-01-07 アボット・ラボラトリーズ 結晶形態のラパマイシン類似体
JP2013536182A (ja) * 2010-08-04 2013-09-19 メリル ライフ サイエンシズ ピーブィティ．エルティディ 抗増殖特性を有する新規４２−ｏ−（ヘテロアルコキシアルキル）ラパマイシン化合物の調製プロセス
WO2019241789A1 (en) * 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020154447A1 (en) * 2019-01-22 2020-07-30 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
WO2021113665A1 (en) * 2019-12-05 2021-06-10 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof

Also Published As

Publication number Publication date
AU2022209863A1 (en) 2023-09-07
US20220267352A1 (en) 2022-08-25
EP4281463A1 (en) 2023-11-29
KR20230136625A (ko) 2023-09-26
MX2023008634A (es) 2023-10-10
EP4281463A4 (en) 2025-07-23
WO2022159976A1 (en) 2022-07-28
BR112023014287A2 (pt) 2023-11-21
CA3209086A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
US20240131012A1 (en) Rapamycin analogs and uses thereof
JP7727700B2 (ja) ラパマイシン類似体およびその使用
US20220267352A1 (en) Rapamycin analogs and uses thereof
CN116917294A (zh) 雷帕霉素类似物及其用途
HK40105219A (en) Rapamycin analogs and uses thereof
HK40082250A (en) Rapamycin analogs and uses thereof
EA045993B1 (ru) Аналоги рапамицина и их применения
EA049308B1 (ru) Аналоги рапамицина и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118